TELA Bio Appoints New Directors, Adjusts Executive Pay
Ticker: TELA · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1561921
| Field | Detail |
|---|---|
| Company | Tela Bio, Inc. (TELA) |
| Form Type | 8-K |
| Filed Date | Oct 9, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $45,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation
TL;DR
TELA Bio adds two directors and revises CEO/CFO pay packages.
AI Summary
TELA Bio, Inc. announced on October 4, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. David L. Alfery and Mr. Jeffrey S. G. Smith, to its Board, effective immediately. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Mr. Antony J. Loeser, and Chief Financial Officer, Mr. Robert L. Davis, detailing their compensation packages.
Why It Matters
The appointment of new directors and adjustments to executive compensation can signal strategic shifts or confidence in the company's future direction, impacting investor sentiment.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can sometimes precede significant strategic changes or reflect internal dynamics that may carry risks.
Key Players & Entities
- TELA Bio, Inc. (company) — Registrant
- Dr. David L. Alfery (person) — Newly Elected Director
- Mr. Jeffrey S. G. Smith (person) — Newly Elected Director
- Mr. Antony J. Loeser (person) — Chief Executive Officer
- Mr. Robert L. Davis (person) — Chief Financial Officer
FAQ
Who were the new directors appointed to TELA Bio's Board?
Dr. David L. Alfery and Mr. Jeffrey S. G. Smith were elected as new directors to TELA Bio's Board.
When were the new directors' appointments effective?
The appointments of Dr. David L. Alfery and Mr. Jeffrey S. G. Smith were effective immediately as of October 4, 2025.
Which executive officers entered into new employment agreements?
Mr. Antony J. Loeser, Chief Executive Officer, and Mr. Robert L. Davis, Chief Financial Officer, entered into new employment agreements.
What is the principal executive office address for TELA Bio, Inc.?
The principal executive offices are located at 1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania 19355.
What is the SIC code for TELA Bio, Inc.?
The Standard Industrial Classification (SIC) code for TELA Bio, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 1,028 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2025-10-09 16:12:31
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 per share TELA Nasdaq Global Market
- $45,000 — will receive an annual base retainer of $45,000 for her service on the Board. In accor
Filing Documents
- tm2528308d1_8k.htm (8-K) — 27KB
- 0001104659-25-098354.txt ( ) — 189KB
- tela-20251004.xsd (EX-101.SCH) — 3KB
- tela-20251004_lab.xml (EX-101.LAB) — 33KB
- tela-20251004_pre.xml (EX-101.PRE) — 22KB
- tm2528308d1_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Director On October 4, 2025, Lisa Colleran, a member of the Board of Directors (the " Board ") of TELA Bio, Inc. (the " Company "), tendered her resignation from the Board, effective as of October 4, 2025. Ms. Colleran also resigned from her positions as a member of the Nominating and Corporate Governance Committee and the Audit Committee. Ms. Colleran's decision to resign did not result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices. Appointment of Director On October 7, 2025, the Board, upon recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Dr. Betty Jo Rocchio as a member of the Board, effective as of October 9, 2025. Dr. Rocchio will serve as a Class I director, with a term expiring at the Company's 2026 Annual Meeting of Stockholders. Dr. Rocchio, 57, has served as the Executive Vice President, Chief Executive Nurse at Advocate Health, a nonprofit integrated health system, since November 2024. As Chief Executive Nurse, Dr. Rocchio oversees the enterprise nursing structure, which consists of 165,000 full time employees, including 42,000 registered nurses, and is a serving member of the CEO's cabinet. Previously, Dr. Rocchio served as the Senior Vice President, Chief Nurse Executive at Mercy Health System (" Mercy ") from October 2020 to November 2024. At Mercy, Dr. Rocchio held additional roles of System Vice President, Perioperative Performance Acceleration and System Vice President, Chief Nursing Optimization Officer from July 2013 to March 2018 and April 2018 to October 2020, respectively. Dr. Rocchio holds a Bachelor's degree in Nursing and an Associate degree in Business Management from the Franciscan University of Steubenville, a Master's degree in Health Sciences from
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELA BIO, INC. By: /s/ Antony Koblish Name: Antony Koblish Title: Chief Executive Officer and Director Date: October 9, 2025